AnGes Inc. announced that in Phase 1/2a clinical trial in Australia an administration of the DNA vaccine for hypertension was completed to 24 patients as scheduled. Moving forward, an evaluation of the six-month safety and efficacy under double-blinded conditions will be conducted, followed by the evaluation of long-term safety and efficacy, under open-label conditions, for another six months. Study Synopsis: Double-blind, placebo-controlled, clinical study evaluating the safety, tolerability and exploratory efficacy targeting hypertensive patients; Number of subjects enrolled: 24 subjects; Observation period: 12 months. The results of the clinical trial are planned to be published around the fourth quarter of 2020.